MBX Biosciences CEO Increases Shareholding
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy MBX?
Source: Fool
- Share Purchase Transaction: P. Kent Hawryluk, CEO of MBX Biosciences, reported an indirect purchase of 18,500 shares at an average price of $28.41 per share on March 13, 2026, totaling $526,000, indicating his confidence in the company's future prospects.
- Ownership Structure Change: Post-transaction, Hawryluk holds 728,274 shares directly and 486,777 shares indirectly through the P. Kent Hawryluk Revocable Trust, reflecting his commitment to the company's long-term growth strategy.
- Market Performance Context: This purchase represents 1.55% of Hawryluk's total holdings, occurring during a period when MBX shares have appreciated by 270% over the past year, highlighting the company's strong growth potential in the biotech sector.
- Financial Overview: With a market capitalization of $1.4 billion and a net income of -$86.97 million, MBX holds approximately $459 million in cash and investments, which is expected to fund operations into 2029, demonstrating financial stability during its clinical development phase.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBX
Wall Street analysts forecast MBX stock price to rise
8 Analyst Rating
7 Buy
0 Hold
1 Sell
Strong Buy
Current: 28.500
Low
31.97
Averages
59.33
High
80.00
Current: 28.500
Low
31.97
Averages
59.33
High
80.00
About MBX
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MBX Biosciences CEO Increases Shareholding
- Share Purchase Transaction: P. Kent Hawryluk, CEO of MBX Biosciences, reported an indirect purchase of 18,500 shares at an average price of $28.41 per share on March 13, 2026, totaling $526,000, indicating his confidence in the company's future prospects.
- Ownership Structure Change: Post-transaction, Hawryluk holds 728,274 shares directly and 486,777 shares indirectly through the P. Kent Hawryluk Revocable Trust, reflecting his commitment to the company's long-term growth strategy.
- Market Performance Context: This purchase represents 1.55% of Hawryluk's total holdings, occurring during a period when MBX shares have appreciated by 270% over the past year, highlighting the company's strong growth potential in the biotech sector.
- Financial Overview: With a market capitalization of $1.4 billion and a net income of -$86.97 million, MBX holds approximately $459 million in cash and investments, which is expected to fund operations into 2029, demonstrating financial stability during its clinical development phase.
See More
MBX Biosciences Reports Q4 2025 Financial Results
- Financial Performance: MBX Biosciences reported a GAAP EPS of -$0.49 for Q4 2025, indicating ongoing challenges in profitability and reflecting competitive pressures in the market.
- Cash Position: As of December 31, 2025, MBX had cash, cash equivalents, and marketable securities totaling $373.7 million, and subsequently raised an additional $85.4 million through its ATM program on February 4, 2026, enhancing liquidity.
- Net Loss Analysis: The net loss for Q4 2025 was $22.1 million, compared to a net loss of $15.6 million in the same period of 2024, highlighting difficulties in cost control and revenue generation.
- Annual Loss Comparison: The total net loss for 2025 reached $87.0 million, significantly up from $61.9 million in 2024, indicating that the company needs to implement more effective strategies for business expansion and profitability.
See More
Mbx Biosciences Shares Hit Oversold Signal
- Oversold Signal: Mbx Biosciences Inc (Ticker: MBX) saw its RSI drop to 29.1 during Monday's trading, indicating an oversold condition as shares hit a low of $27.98, suggesting that the recent heavy selling may be nearing exhaustion, prompting bullish investors to consider buying opportunities.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 44.9, MBX's 29.1 RSI indicates relative weakness, potentially attracting investors looking for rebounds, especially amid increasing market volatility.
- Historical Performance: MBX's 52-week low stands at $4.8069 per share, with a high of $44.89, and the last trade at $27.94 reflects significant price fluctuations over the past year, necessitating careful risk assessment by investors.
- Investor Sentiment: Although the current stock price is in the oversold territory, investor sentiment may be influenced by short-term market fluctuations, requiring close monitoring of future market trends to determine entry points.
See More
MBX Biosciences Completes EOP2 Meeting with FDA for Canvuparatide
- Successful EOP2 Meeting: MBX Biosciences successfully completed an End-of-Phase 2 meeting with the FDA, discussing the Phase 3 trial design for canvuparatide aimed at chronic hypoparathyroidism, marking a significant milestone in the drug development process.
- Phase 3 Trial Design: The planned Phase 3 trial, set to initiate in Q3 2026, will enroll approximately 160 patients randomized in a 3:1 ratio to evaluate the efficacy and safety of canvuparatide, potentially offering patients a more convenient treatment option.
- Drug Design Advantages: Canvuparatide is designed as a long-acting hormone replacement therapy that aims to restore physiological PTH activity with a once-weekly dosing regimen, which is expected to significantly enhance patients' quality of life and meet the urgent market demand for new treatment options.
- Orphan Drug Designation: The drug has received orphan drug designation from the European Medicines Agency, further supporting its clinical development in Europe and demonstrating MBX's strategic focus on the global market and chronic hypoparathyroidism.
See More
MBX Biosciences Completes FDA Meeting, Advances New Drug Trial
- Clinical Trial Progress: MBX Biosciences successfully completed an End-of-Phase 2 meeting with the FDA to discuss the Phase 3 trial design for canvuparatide, marking a significant milestone in the company's drug development journey.
- Patient Recruitment Plan: The company plans to initiate recruitment of approximately 160 patients for a Phase 3 double-blind placebo-controlled trial in Q3 2026, with a 3:1 randomization ratio aimed at assessing the efficacy and safety of canvuparatide.
- Drug Design Advantages: Canvuparatide is designed as a long-acting hormone replacement therapy that aims to restore physiological PTH activity through a convenient once-weekly dosing regimen, which is expected to set a new standard of care for hypoparathyroidism, addressing patient needs for less burdensome treatment options.
- European Market Recognition: The drug has received orphan drug designation from the European Medicines Agency, further supporting its clinical development in Europe and demonstrating MBX's potential for global market expansion.
See More
Overview of 13D Filings
- Definition of 13D Filings: 13D filings are disclosures required to be submitted to the SEC within 10 days when an entity acquires more than 5% of any class of a company's securities, aimed at enhancing market transparency.
- Purpose of Disclosure: The primary purpose of these filings is to inform investors about the holdings of major shareholders and their potential impact on corporate governance and strategic decisions, thereby aiding market participants in making more informed investment choices.
- Compliance Requirements: Under U.S. securities law, any investor holding more than 5% must timely submit a 13D filing to ensure that all market participants have access to relevant information, thus maintaining market fairness.
- Market Impact: The disclosure of 13D filings can trigger market interest in the related companies, influencing their stock price volatility, especially when investors speculate on the intentions and future plans of major shareholders.
See More
MBX Biosciences CEO Increases Shareholding
- Share Purchase Transaction: P. Kent Hawryluk, CEO of MBX Biosciences, reported an indirect purchase of 18,500 shares at an average price of $28.41 per share on March 13, 2026, totaling $526,000, indicating his confidence in the company's future prospects.
- Ownership Structure Change: Post-transaction, Hawryluk holds 728,274 shares directly and 486,777 shares indirectly through the P. Kent Hawryluk Revocable Trust, reflecting his commitment to the company's long-term growth strategy.
- Market Performance Context: This purchase represents 1.55% of Hawryluk's total holdings, occurring during a period when MBX shares have appreciated by 270% over the past year, highlighting the company's strong growth potential in the biotech sector.
- Financial Overview: With a market capitalization of $1.4 billion and a net income of -$86.97 million, MBX holds approximately $459 million in cash and investments, which is expected to fund operations into 2029, demonstrating financial stability during its clinical development phase.
See More
MBX Biosciences Reports Q4 2025 Financial Results
- Financial Performance: MBX Biosciences reported a GAAP EPS of -$0.49 for Q4 2025, indicating ongoing challenges in profitability and reflecting competitive pressures in the market.
- Cash Position: As of December 31, 2025, MBX had cash, cash equivalents, and marketable securities totaling $373.7 million, and subsequently raised an additional $85.4 million through its ATM program on February 4, 2026, enhancing liquidity.
- Net Loss Analysis: The net loss for Q4 2025 was $22.1 million, compared to a net loss of $15.6 million in the same period of 2024, highlighting difficulties in cost control and revenue generation.
- Annual Loss Comparison: The total net loss for 2025 reached $87.0 million, significantly up from $61.9 million in 2024, indicating that the company needs to implement more effective strategies for business expansion and profitability.
See More
Mbx Biosciences Shares Hit Oversold Signal
- Oversold Signal: Mbx Biosciences Inc (Ticker: MBX) saw its RSI drop to 29.1 during Monday's trading, indicating an oversold condition as shares hit a low of $27.98, suggesting that the recent heavy selling may be nearing exhaustion, prompting bullish investors to consider buying opportunities.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 44.9, MBX's 29.1 RSI indicates relative weakness, potentially attracting investors looking for rebounds, especially amid increasing market volatility.
- Historical Performance: MBX's 52-week low stands at $4.8069 per share, with a high of $44.89, and the last trade at $27.94 reflects significant price fluctuations over the past year, necessitating careful risk assessment by investors.
- Investor Sentiment: Although the current stock price is in the oversold territory, investor sentiment may be influenced by short-term market fluctuations, requiring close monitoring of future market trends to determine entry points.
See More
MBX Biosciences Completes EOP2 Meeting with FDA for Canvuparatide
- Successful EOP2 Meeting: MBX Biosciences successfully completed an End-of-Phase 2 meeting with the FDA, discussing the Phase 3 trial design for canvuparatide aimed at chronic hypoparathyroidism, marking a significant milestone in the drug development process.
- Phase 3 Trial Design: The planned Phase 3 trial, set to initiate in Q3 2026, will enroll approximately 160 patients randomized in a 3:1 ratio to evaluate the efficacy and safety of canvuparatide, potentially offering patients a more convenient treatment option.
- Drug Design Advantages: Canvuparatide is designed as a long-acting hormone replacement therapy that aims to restore physiological PTH activity with a once-weekly dosing regimen, which is expected to significantly enhance patients' quality of life and meet the urgent market demand for new treatment options.
- Orphan Drug Designation: The drug has received orphan drug designation from the European Medicines Agency, further supporting its clinical development in Europe and demonstrating MBX's strategic focus on the global market and chronic hypoparathyroidism.
See More
MBX Biosciences Completes FDA Meeting, Advances New Drug Trial
- Clinical Trial Progress: MBX Biosciences successfully completed an End-of-Phase 2 meeting with the FDA to discuss the Phase 3 trial design for canvuparatide, marking a significant milestone in the company's drug development journey.
- Patient Recruitment Plan: The company plans to initiate recruitment of approximately 160 patients for a Phase 3 double-blind placebo-controlled trial in Q3 2026, with a 3:1 randomization ratio aimed at assessing the efficacy and safety of canvuparatide.
- Drug Design Advantages: Canvuparatide is designed as a long-acting hormone replacement therapy that aims to restore physiological PTH activity through a convenient once-weekly dosing regimen, which is expected to set a new standard of care for hypoparathyroidism, addressing patient needs for less burdensome treatment options.
- European Market Recognition: The drug has received orphan drug designation from the European Medicines Agency, further supporting its clinical development in Europe and demonstrating MBX's potential for global market expansion.
See More
Overview of 13D Filings
- Definition of 13D Filings: 13D filings are disclosures required to be submitted to the SEC within 10 days when an entity acquires more than 5% of any class of a company's securities, aimed at enhancing market transparency.
- Purpose of Disclosure: The primary purpose of these filings is to inform investors about the holdings of major shareholders and their potential impact on corporate governance and strategic decisions, thereby aiding market participants in making more informed investment choices.
- Compliance Requirements: Under U.S. securities law, any investor holding more than 5% must timely submit a 13D filing to ensure that all market participants have access to relevant information, thus maintaining market fairness.
- Market Impact: The disclosure of 13D filings can trigger market interest in the related companies, influencing their stock price volatility, especially when investors speculate on the intentions and future plans of major shareholders.
See More
